semustine has been researched along with Melanoma in 44 studies
Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and fifty-seven evaluable patients with advanced metastatic malignant melanoma were randomly assigned to receive either methyl-CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks) (82 patients) or a combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc) in the periumbilical area (75 patients)." | 9.05 | Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. ( Cohen, MH; Schoenfeld, D; Wolter, J, 1980) |
| "The nephrotoxicity of semustine (methyl-CCNU) has been studied in 45 adult patients with surgically resected Stage I or II malignant melanoma who received this drug as adjuvant chemotherapy." | 9.05 | Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. ( Fisher, RI; Jensen-Akula, M; Mandard, JC; Micetich, KC, 1981) |
| "Patients with advanced malignant melanoma were randomly assigned to treatment with cylcophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP)." | 9.04 | Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma. ( Byrne, MJ, 1976) |
| "One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU." | 7.67 | Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. ( Amato, DA; Cunningham, TJ; Falkson, G; Kaufman, JH; Von Hoff, DD, 1984) |
| "Cells from a resistant ("Gr II") and a sensitive ("Str") human melanoma xenograft were incubated in vitro with O6-methylguanine for 2 h, subsequently treated with 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea (MeCCNU) for 1 h and then plated in soft agar." | 7.67 | Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells. ( Dempke, W; Nehls, P; Osieka, R; Schmidt, CG; Soll, D; Wandl, U, 1987) |
| "In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma." | 7.67 | Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. ( Amato, DA; Ash, A; Borden, EC; Bruckner, H; Creech, RH; Cunningham, TJ; Falkson, G; Guerry, D; Savlov, ED, 1987) |
| "Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU)." | 7.66 | Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Schutt, AJ, 1982) |
| "One hundred and fifty-seven evaluable patients with advanced metastatic malignant melanoma were randomly assigned to receive either methyl-CCNU (MeCCNU) (200 mg/m2 orally every 6 weeks) (82 patients) or a combination of MeCCNU, chlorpromazine (50 mg/m2 im), and caffeine (600 mg/m2 sc) in the periumbilical area (75 patients)." | 5.05 | Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma. ( Cohen, MH; Schoenfeld, D; Wolter, J, 1980) |
| "The nephrotoxicity of semustine (methyl-CCNU) has been studied in 45 adult patients with surgically resected Stage I or II malignant melanoma who received this drug as adjuvant chemotherapy." | 5.05 | Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. ( Fisher, RI; Jensen-Akula, M; Mandard, JC; Micetich, KC, 1981) |
| "Patients with advanced malignant melanoma were randomly assigned to treatment with cylcophosphamide and vincristine (CV) or cyclophosphamide, vincristine, and procarbazine (CVP)." | 5.04 | Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma. ( Byrne, MJ, 1976) |
| "One hundred twenty-two patients with disseminated malignant melanoma were randomized using an unbalanced randomization to receive chlorozotocin, neocarzinostatin, or MeCCNU." | 3.67 | Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. ( Amato, DA; Cunningham, TJ; Falkson, G; Kaufman, JH; Von Hoff, DD, 1984) |
| "Cells from a resistant ("Gr II") and a sensitive ("Str") human melanoma xenograft were incubated in vitro with O6-methylguanine for 2 h, subsequently treated with 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea (MeCCNU) for 1 h and then plated in soft agar." | 3.67 | Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells. ( Dempke, W; Nehls, P; Osieka, R; Schmidt, CG; Soll, D; Wandl, U, 1987) |
| "In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma." | 3.67 | Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. ( Amato, DA; Ash, A; Borden, EC; Bruckner, H; Creech, RH; Cunningham, TJ; Falkson, G; Guerry, D; Savlov, ED, 1987) |
| "Twenty-six patients with disseminated malignant melanoma received an oral regimen of mitolactol and semustine (methyl-CCNU)." | 3.66 | Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Schutt, AJ, 1982) |
| "Human melanoma xenografts in immune-deprived mice have been used to assess the value of the agar diffusion chamber for chemosensitivity testing." | 3.66 | Use of the agar diffusion chamber for the exposure of human tumor cells to drugs. ( Selby, PJ; Steel, GG, 1982) |
| "The therapeutic usefulness of chlorpromazine (CPZ) and caffeine (CAF) in combination with selected nitrosoureas was investigated in mice bearing L1210 leukemia, Lewis lung carcinoma, and B16 melanoma." | 3.66 | Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors. ( Dykes, DJ; Laster, WR; Rose, WC; Schabel, FM; Trader, MW, 1978) |
| "Single doses of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea caused transient suppression of [3H]thymidine incorporation into DNA in bone marrow and gastrointestinal mucosa and more prolonged inhibition of such incorporation in B16 melanoma." | 3.65 | Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy. ( Brereton, HD; Bryant, TL; Young, RC, 1975) |
| " Further, both disease staging and drug dosage have been shown to influence cure rates of combined-modality treatment." | 2.35 | Concepts for treatment of micrometastases developed in murine systems. ( Schabel, FM, 1976) |
| " The results imply that dosage scheduling in the treatment of murine melanomas must be individualized." | 1.26 | Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas. ( Hill, GJ; Hill, HZ, 1982) |
| " Dose-response curves were obtained and the surviving fraction at drug levels estimated to be achieved in man was used as a measure of in vitro drug sensitivity." | 1.26 | In vitro chemosensitivity tests on xenografted human melanomas. ( Bateman, AE; Selby, PJ; Steel, GG; Towse, GD, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (95.45) | 18.7374 |
| 1990's | 2 (4.55) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osieka, R | 6 |
| Glatte, P | 4 |
| Pannenbäcker, R | 2 |
| Schmidt, CG | 5 |
| Von Hoff, DD | 1 |
| Amato, DA | 2 |
| Kaufman, JH | 1 |
| Falkson, G | 2 |
| Cunningham, TJ | 2 |
| Kemeny, N | 1 |
| Raina, S | 1 |
| Hill, HZ | 3 |
| Hill, GJ | 3 |
| Rush, BF | 1 |
| Kirkwood, JM | 1 |
| Marsh, JC | 1 |
| Cohen, MH | 1 |
| Schoenfeld, D | 2 |
| Wolter, J | 2 |
| Fisher, RI | 2 |
| Terry, WD | 1 |
| Hodes, RJ | 1 |
| Rosenberg, SA | 1 |
| Makuch, R | 1 |
| Gordon, HG | 1 |
| Fisher, SG | 1 |
| Micetich, KC | 1 |
| Jensen-Akula, M | 1 |
| Mandard, JC | 1 |
| Knost, JA | 1 |
| Reynolds, V | 1 |
| Greco, FA | 1 |
| Oldham, RK | 1 |
| Creagan, ET | 1 |
| Ahmann, DL | 3 |
| Schutt, AJ | 1 |
| Green, SJ | 1 |
| Selby, PJ | 2 |
| Steel, GG | 2 |
| Haedecke, U | 1 |
| Griswold, DP | 2 |
| Corbett, TH | 1 |
| Schabel, FM | 5 |
| Bateman, AE | 1 |
| Towse, GD | 1 |
| Coates, AS | 1 |
| Segelov, E | 1 |
| Livingston, RB | 1 |
| Einhorn, LH | 2 |
| Bodey, GP | 1 |
| Burgess, MA | 1 |
| Freireich, EJ | 1 |
| Gottlieb, JA | 1 |
| Mabel, JA | 1 |
| Merker, PC | 1 |
| Sturgeon, ML | 1 |
| Wodinsky, I | 1 |
| Geran, RI | 1 |
| Furnas, B | 1 |
| Costanza, ME | 1 |
| Nathanson, L | 1 |
| Colsky, J | 1 |
| Regelson, W | 1 |
| Cunningham, T | 1 |
| Sedransk, N | 1 |
| Kokoschka, EM | 1 |
| Luger, T | 1 |
| Micksche, M | 1 |
| Berd, D | 2 |
| Wilson, EJ | 1 |
| Bellet, RE | 2 |
| Mastrangelo, MJ | 2 |
| Miller, CL | 1 |
| Pfaller, M | 1 |
| Weiss, K | 1 |
| Galin, M | 1 |
| Berkelhammer, J | 1 |
| Prehn, RT | 1 |
| Didolkar, MS | 1 |
| Baffi, RR | 1 |
| Catane, R | 1 |
| Kaufman, J | 1 |
| Holyoke, ED | 1 |
| Lee, W | 1 |
| Moore, RP | 1 |
| Wampler, GL | 1 |
| Rose, WC | 1 |
| Trader, MW | 1 |
| Dykes, DJ | 2 |
| Laster, WR | 1 |
| Bisel, HF | 1 |
| Edmonson, JH | 1 |
| Hahn, RG | 1 |
| Eagan, RT | 1 |
| O'Connell, MJ | 1 |
| Frytak, S | 1 |
| Byrne, MJ | 1 |
| Wittes, RE | 1 |
| Hong, WK | 1 |
| Gatchell, L | 1 |
| Krakoff, IH | 1 |
| Golbey, RB | 1 |
| Brereton, HD | 1 |
| Bryant, TL | 1 |
| Young, RC | 1 |
| Luce, JK | 1 |
| Boaziz, C | 1 |
| Breau, JL | 1 |
| Morere, JF | 1 |
| Israël, L | 1 |
| Paietta, E | 1 |
| Papenhausen, P | 1 |
| Ciobanu, N | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 1 |
| Dempke, W | 1 |
| Nehls, P | 1 |
| Wandl, U | 1 |
| Soll, D | 1 |
| Bruckner, H | 1 |
| Guerry, D | 1 |
| Ash, A | 1 |
| Borden, EC | 1 |
| Creech, RH | 1 |
| Savlov, ED | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Carter, SK | 1 |
5 reviews available for semustine and Melanoma
| Article | Year |
|---|---|
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
Concepts for treatment of micrometastases developed in murine systems.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Cricetinae; Cyclop | 1976 |
Nitrosoureas: a review of experimental antitumor activity.
Topics: Animals; Carmustine; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy, | 1976 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interl | 1991 |
Methyl-CCNU inclinical cancer therapy.
Topics: Animals; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous | 1974 |
12 trials available for semustine and Melanoma
| Article | Year |
|---|---|
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
Topics: Caffeine; Chlorpromazine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Melanoma; Nit | 1980 |
Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
Topics: BCG Vaccine; Cell Line; Clinical Trials as Topic; Female; Humans; Male; Melanoma; Mitomycins; Neopla | 1981 |
Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Humans; Kidney; | 1981 |
Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
Topics: Adolescent; Adult; Aged; BCG Vaccine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Lymph N | 1982 |
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Leuko | 1977 |
Results with methyl-CCNU and DTIC in metastatic melanoma.
Topics: Brain Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dacarbazine; Drug | 1977 |
[Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
Topics: Bacterial Vaccines; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Nitrosourea Compo | 1978 |
Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cell Line; Cytotoxicity, Immunologic; Drug Therapy, | 1979 |
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Administration Schedule; Drug | 1976 |
Nitrosoureas in the management of disseminated malignant melanoma.
Topics: Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; | 1976 |
Cyclophosphamide, vincristine and procarbazine in the treatment of malignant melanoma.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Fem | 1976 |
28 other studies available for semustine and Melanoma
| Article | Year |
|---|---|
Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Female; Humans; | 1983 |
Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis | 1984 |
Studies on drug resistance in a human melanoma xenograft system.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Models, Ani | 1984 |
Scheduling of combination chemotherapy for a murine melanoma, with the subrenal capsular assay.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedule; | 1984 |
In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome.
Topics: Animals; Biological Assay; Biotransformation; Cell Survival; Clone Cells; Dacarbazine; Drug Evaluati | 1983 |
Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
Topics: Animals; Cell Line; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Female; Me | 1982 |
Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukocyte Count; Leukopenia; Male; | 1982 |
Use of the agar diffusion chamber for the exposure of human tumor cells to drugs.
Topics: Agar; Animals; Antineoplastic Agents; Cell Survival; Diffusion; Doxorubicin; Drug Evaluation, Precli | 1982 |
[Enhancement of MeCCNU potency (chemosensitization) by misonidazole in a human melanoma xenograft system].
Topics: Animals; Cell Line; Drug Interactions; Female; Humans; Melanoma; Mice; Mice, Nude; Misonidazole; Neo | 1982 |
Clonogenicity and growth of experimental tumors in relation to developing resistance and therapeutic failure.
Topics: Animals; Clone Cells; Cyclophosphamide; Drug Resistance; Humans; Leukemia L1210; Melanoma; Mice; Neo | 1981 |
In vitro chemosensitivity tests on xenografted human melanomas.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Hu | 1980 |
Long term response to chemotherapy in patients with visceral metastatic melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 1994 |
COMB (cyclophosphamide, oncovin, methyl-CCNU, and bleomycin): a four-drug combination in solid tumors.
Topics: Bleomycin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Drug | 1975 |
Combination chemotherapy against B16 melanoma: bleomycin/vinblastine, bleomycin/cis-diamminedichloroplatinum, 5-fluorouracil/BCNU and 5-fluorouracil/methyl-CCNU.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Cisplatin; Dose-Response Relationship, Drug; | 1978 |
Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.
Topics: Adult; Aged; Antibody Formation; Antigens; Dinitrochlorobenzene; Escherichia coli; Female; Hemocyani | 1979 |
Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
Topics: Animals; Cell Count; Dacarbazine; Female; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasm | 1979 |
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Topics: Dacarbazine; Drug Evaluation; Drug Resistance; Humans; Melanoma; Nitrosourea Compounds; Procarbazine | 1977 |
Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy.
Topics: Brain Neoplasms; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Pu | 1978 |
Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
Topics: Animals; Caffeine; Carmustine; Chlorpromazine; Drug Synergism; Drug Therapy, Combination; Female; Le | 1978 |
Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
Topics: Bone Marrow; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Met | 1977 |
Inhibition and recovery of DNA synthesis in host tissues and sensitive and resistant B16 melanoma after 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea, a predictor of therapeutic efficacy.
Topics: Animals; Bone Marrow; Cell Division; Depression, Chemical; DNA; DNA, Neoplasm; Gastric Mucosa; Intes | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; D | 1975 |
Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor.
Topics: Animals; Carmustine; Cell Line; Cells, Cultured; Melanoma; Mice; Neoplasm Transplantation; Neoplasms | 1976 |
Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
Topics: Animals; Caffeine; Chlorpromazine; Drug Resistance; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Tra | 1989 |
Biphenotypic leukemia with unusual chromosomal translocation in a patient treated for melanoma.
Topics: Acute Disease; Adult; Antibodies, Monoclonal; Antigens, Neoplasm; Chromosomes, Human, 1-3; Histocomp | 1986 |
Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Cell Division; Colony-Forming Units Assay; Cross-Linking Re | 1987 |
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1987 |
Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Caffeine; Chlorpromazine; DNA | 1986 |